Doctors should ask their patients to write online reviews—and then respond to feedback: It will go a long way in attracting and retaining patients.

Trump issues executive order to make healthcare prices more transparent: Price rules finalized during his first term haven’t had an impact. Could it be different this time around?

Talks of a Walgreens take-private sale are ramping up again: Walgreens could be divided into three parts if the sale proceeds. We explore the likelihood of a deal going through and what it means for Walgreens’ future.

US docs spend up to 3 hours per week correcting AI: Physicians’ liability concerns with AI can be addressed by having them involved with technology purchasing decisions.

Only 18% of consumers have ever asked their doctor about a drug ad: But when they do, many patients walk away with a prescription for that medication. We explore how pharma marketers can get the most out of their ad campaigns.

Hims & Hers will still sell compounded semaglutide to some patients: The company isn’t ready to admit defeat in the battle between compounded GLP-1 sellers and Big Pharma. But Hims’ competitive advantage in the weight loss drug market is getting weaker.

The Ozempic shortage is over: We explore how an FDA decision impacts compounded weight loss drug sellers like Hims & Hers and patients who are prescribed GLP-1s.

HHS instructs CDC to shelve vaccine ads, including for the flu: RFK Jr. was at the helm of a decision to halt the CDC’s vaccine-focused advertisements—an early indicator of the steps he’s willing to take in his new role as HHS Secretary.

DOJ will examine UnitedHealth’s Medicare billing practices: The Trump administration has made “waste, fraud, and abuse” a rallying cry. Now, we find out how serious they are about it.

“Dr. AI” is the new “Dr. Google”: 60% of US consumers have used AI for health guidance. Healthcare marketers and providers should educate the public on responsible use of AI for medical purposes.

Hims & Hers moves into at-home testing: Its recent acquisition of a small lab testing company could have a big payoff.

Talkspace posts its first full year of profitability: But it’s not all rosy. It’s catching heat for sending teens’ data to social media platforms. Talkspace must be sure not to spoil its prosperity by damaging its reputation.

Another full-body medical scan startup raises its Series B: Even though the value of full-body scans is up for debate in medical communities, it’s hard to see the hype fading anytime soon.

Docs are using AI more, and are more excited about its potential: But physicians want more regulatory oversight before they completely trust the tech. Recent workforce cuts at the FDA could make this difficult to achieve.

RFK to lead Trump’s Make America Healthy Again commission: Trump’s executive order outlines policies and actions that could impact medication access for children, how quickly drugs get to market, and how federal health agencies conduct research.

How RFK Jr.'s HHS Secretary confirmation could impact pharma: Brands and marketers may need to recalibrate strategies for vaccine messaging, GLP-1 medication access, and drug advertising.

Apple launches new health study: Its experience conducting health studies for product development positions the company well to roll out new health-tracking features and capabilities.

CVS gives investors hope for a better 2025: The key to satisfying Wall Street is to stabilize Aetna. Here’s how CVS plans to make it happen.

Doctors take issue with NYU Langone Health’s Super Bowl ad: They’re largely questioning the not-for-profit’s choice to pay $8M+ for the ad. We explore why health systems would be better off advertising in local markets than national TV events.

Everyone is talking about Hims’ Super Bowl weight loss drug ad: The reaction has been largely negative. We examine why it’s a gamble that will likely pay off for Hims.